To test the hypothesis that pancreas transplantation using the more physiologic method of portal venous-enteric (PE) drainage could be performed without compromising patient and graft outcome, compared with the standard method of systemic venous-bladder (SB) drainage.
Objective
To test the hypothesis that pancreas transplantation using the more physiologic method of portal venous-enteric (PE) drainage could be performed without compromising patient and graft outcome, compared with the standard method of systemic venous-bladder (SB) drainage.
Methods
Between November 1995 and November 1998, the authors prospectively followed up 20 consecutive patients with SB drainage followed by 20 consecutive patients with PE drainage. All patients underwent simultaneous pancreas-kidney transplantation, and all were immunosuppressed with antilymphocyte serum, cyclosporin, azathioprine, and steroids.
Results
The actuarial patient survival rate at 1 year was 95% in the SB group and 100% in the PE group. Death-censored kidney graft survival was 100% in both groups; pancreas graft survival was 95% in the SB group and 100% in the PE group. The mean initial hospital stay was 15 days for both groups. However, during the first 6 months after transplantation, the SB group required more medical day-unit visits, mostly for treatment of metabolic acidosis and dehydration. The incidence of urinary tract infections was similar in both groups. The incidence of cytomegalovirus infections was significantly less in the PE group. The incidence of acute rejection was 37% in the SB group and 15% in the PE group. Mean serum creatinine levels 6 months after transplantation were significantly lower in the PE group than in the SB group. Glycemic control was excellent in both groups, but fasting serum insulin levels were significantly lower in the PE group.
Conclusions
The PE method of pancreas transplantation can be performed with excellent patient and graft outcomes.
Pancreas transplantation is the only form of self-regulating total endocrine replacement therapy that has been successful in the treatment of diabetes. According to the Inter-national Pancreas Transplant Registry, more than 11,000 pancreas transplants have been performed worldwide to date. 1 The 1-year patient survival rate currently exceeds 90%, and more than 80% of patients are free of exogenous insulin requirements with no dietary restrictions 1 year after transplantation.
Several techniques of pancreas transplantation have been described since the original transplant was performed in 1966. 2 Currently, the most common technique in North America involves whole-organ transplantation with anastomosis of the duodenal segment to the bladder for drainage of the exocrine secretions, and systemic venous drainage of the pancreatic hormones. This technique allows measure-ment of urinary amylase as a marker for graft rejection, but the chronic loss of pancreatic secretions can result in dehydration, electrolyte abnormalities, local bladder irritation, and allograft pancreatitis. 3, 4 Although these complications are often managed easily, 20% to 30% of patients ultimately require intestinal diversion of the exocrine secretions. 5, 6 In 1993, Gaber et al 7 pioneered a new technique in humans with portal venous drainage and enteric exocrine drainage. Early results have shown that enteric exocrine drainage is associated with significantly fewer postoperative complications than bladder exocrine drainage, 5, 8 and metabolic studies have shown a reduction of peripheral hyperinsulinemia with portal venous drainage. 9, 10 Despite the obvious physiologic attractiveness of portal venous and enteric drainage, few programs have adopted this method.
The purpose of our study was to compare the outcome of a consecutive series of patients who received pancreas transplants using the portal venous-enteric (PE) technique with those whose graft was transplanted with the standard systemic venous-bladder (SB) technique.
METHODS

Patients
The pancreas-kidney transplantation program at Toronto General Hospital was initiated in November 1995, and as of July 1999 50 transplants had been performed. The pancreas was transplanted using the SB technique in the first 20 patients; as of October 1997, the PE technique was attempted in all subsequent recipients. This report focuses on the outcome of the first 40 patients, for whom there is a minimum of 6 months follow-up since transplantation.
Recipient characteristics are summarized in Table 1 . There were no significant differences in recipient age, gender, duration of diabetes, duration and type of dialysis, or prevalence of retinopathy and neuropathy between the two Portal-Enteric Pancreas Transplantation groups. The prevalence of coexisting cardiovascular comorbidity was also similar.
Organ Procurement and Preservation
The characteristics of the donors are summarized in Table  2 . Our surgical team, using the en bloc liver-pancreas procurement technique with ex vivo separation of the organs, retrieved all grafts. Povidone-iodine (50 mL) was injected into the duodenum through a nasogastric tube during procurement. All grafts were preserved in University of Wisconsin solution (Viaspan, DuPont, Wilmington, DE). The pancreas was prepared for transplantation using a donor iliac artery bifurcation graft, as described by others. 11 Organ allocation was based on ABO blood group compatibility, presence of a negative T-cell cross-match, and waiting time.
No attempt was made to match donor and recipient human leukocyte antigens or to avoid cytomegalovirus (CMV) mismatches.
Surgical Procedures
The recipient procedure was performed through a midline abdominal incision. The kidney was implanted first and revascularized with the external iliac vessels. The ureter was anastomosed to the bladder over a Silastic double-J stent using an extravesical technique. SB-drained pancreas grafts were placed in the right iliac fossa; the artery and vein were anastomosed to the native common iliac artery and external iliac vein, respectively, and the duodenum was anastomosed to the bladder in two layers with 4 -0 Maxon. For the PE-drained pancreas, the portal vein of the pancreas was anastomosed end to side to the recipient superior mesenteric vein, which was exposed at the root of the transverse mesocolon ( Fig. 1 ). The donor iliac arterial graft was tunneled posteriorly through an aperture created in the small bowel mesentery and anastomosed end to side to the native common iliac artery. In some instances, the donor arterial graft was too short to reach the native common iliac artery easily. We now routinely anastomose a segment of donor innominate artery to the native common iliac artery before the pancreas is brought into the surgical field to provide additional length. 12 The duodenal segment was anastomosed to a Roux-en-Y limb of jejunum in two layers with 4 -0 Maxon. An indwelling Foley catheter was left in the bladder for 10 days for SB-drained and 4 to 5 days for PE-drained pancreas grafts.
Postoperative Management and Immunosuppression
All patients received aspirin (80 mg/day) for thrombosis prophylaxis. Antimicrobial prophylaxis consisted of intravenous cefazolin for 24 hours, mycostatin mouthwash for 3 months, and oral trimethoprim-sulfamethoxasole for 1 year. CMV prophylaxis, consisting of intravenous ganciclovir for 7 to 14 days followed by oral ganciclovir (3 g/day) for 3 months, was given to all CMV-positive recipients and to those who received CMV-positive organs.
All patients received induction therapy with rabbit antithymocyte serum (0.1 mL/kg/day) for 7 to 10 days and triple-drug maintenance therapy. Steroid therapy began with 500 mg intravenous methylprednisolone given during surgery, followed by a rapid taper from 200 mg/day to 20 mg/day during 5 days; prednisone was continued at 20 mg/day and tapered to 5 mg/day by 1 year. All patients were treated with azathioprine at 1 to 1.5 mg/kg. Neoral cyclosporin (Novartis, Montreal, Quebec, Canada) was started on posttransplant day 4 or 5, with dosages adjusted to maintain whole-blood trough values of 300 to 400 g/L by monoclonal radioimmunoassay. Biopsy-confirmed rejection episodes were treated initially with methylprednisolone (500 mg/day) for 3 days. Steroid-resistant episodes were treated with a course of OKT3 (5 mg/day; Muromonab, Orthobiotech, Raritan, NJ) for 7 to 10 days. Some patients with rejection or drug toxicity were converted from cyclosporin to tacrolimus (Prograf; Fujisawa, Markham, Ontario, Canada) or from azathioprine to mycophenolate mofetil (Cellcept; Roche Pharmaceuticals, Mississauga, Ontario, Canada).
Postoperative Monitoring
After surgery, serum creatinine, amylase, and glucose levels were closely monitored. Glycosylated hemoglobin levels were measured every 3 months. An oral glucose tolerance test (OGTT) was performed in all patients at 3 months, with blood samples assayed for glucose and insulin concentrations. Blood glucose concentration was measured by the hexokinase G-6-PDH assay (Olympus America Inc., Melville, NY). Plasma insulin concentration was measured by radioimmunoassay (Pharmacia and Upjohn Diagnostics, Uppsala, Sweden).
Statistical Analysis
Continuous variables, which are reported as mean Ϯ standard deviation, were compared with Student t tests. Categorical data, which are presented as rates, were compared by the chi-square test. Patient and graft survival curves were calculated by the Kaplan-Meier method, with differences between the two groups compared by the logrank test. P Ͻ .05 was considered significant.
RESULTS
The duration of the surgical procedure was similar in both groups (5.4 Ϯ 0.8 and 5.2 Ϯ 0.8 hours for SB and PE, respectively, P ϭ .07). Mean intraoperative transfusion requirements in the SB and PE groups were 0.6 Ϯ 1.1 and 0.7 Ϯ 0.7 units, respectively (not significant). All pancreas grafts functioned immediately after transplantation, with all patients achieving insulin independence within 24 to 48 hours. Nonocclusive thrombus was detected incidentally in the splenic vein of the pancreas graft by duplex ultrasonography during the initial hospital stay in two patients in each group. All were anticoagulated with heparin initially, followed by coumadin for 3 months; follow-up ultrasonography revealed resolution of the thrombus in all patients. One patient in each group required dialysis briefly after transplantation. Reoperation was required for one patient in the SB group to ligate an arteriovenous fistula that developed in the pancreas graft and four patients in the PE group (bleeding in one patient, partial wound dehiscence in one, negative laparotomy in two). Lower gastrointestinal bleeding requiring blood transfusion developed in two patients in the PE group; in both cases the bleeding stopped spontaneously. The initial hospital stay was 15 Ϯ 3 and 13 Ϯ 4 days in the SB and PE groups, respectively (not significant).
The respective 1-year patient survival rates in the SB and PE groups were 95% and 100% after a mean follow-up of 29 Ϯ 9 and 14 Ϯ 5 months (Fig. 2) . In the SB group, one patient died on postoperative day 10 of a sudden cardiac Portal-Enteric Pancreas Transplantation arrhythmia, and another died at 23 months of metastatic colon adenocarcinoma. One patient in the SB group lost function of the pancreas at 13 months, presumably from rejection, but the kidney continues to function well. None of the grafts in the PE group were lost as of this writing. During the first 6 months after transplantation, 68% of the SB patients and 64% of the PE patients required at least one readmission to the hospital. The mean number of readmissions per patient was 1.4 and 1.2 for the SB and PE patients, respectively. The total hospital stay during the first 6 months in the SB (22 Ϯ 8 days) and PE (17 Ϯ 7 days) groups was also similar. However, the SB group required more medical dayunit visits (4.9 vs. 0.3 per patient; P Ͻ .0001), mostly for treatment of metabolic acidosis and dehydration ( Table 3) .
All the patients in the SB group required supplemental oral bicarbonate (1.2-4.8 g/day) to maintain their acid-base balance, whereas none was required in the PE patients. Despite therapy, symptomatic dehydration and acidosis were significantly more common among patients in the SB group than the PE group (see Table 3 ). One patient in the SB group subsequently underwent conversion from bladder to enteric drainage for intractable dehydration and acidosis at 22 months. Pancreatic exocrine leaks did not occur in any patient in either group. Allograft pancreatitis developed in two patients in the SB group that resolved after draining the bladder temporarily with an indwelling Foley catheter.
There were no significant differences in the number of urinary tract infections and other infections (e.g., wound, central line), but the incidence of CMV infection was significantly lower in the PE group. In the PE group, three patients required surgical drainage of lymphoceles that developed around the kidney graft, and another patient underwent appendectomy for appendicitis. There was no significant difference in the cumulative incidence of acute rejection in the SB and PE groups (37% and 15%, respectively; P ϭ .2) during the entire follow-up (Fig. 3 ). The mean time interval between transplantation and the first rejection episode was 4.2 Ϯ 2.9 months in the SB group and 8.9 Ϯ 6.7 months in the PE group (P ϭ .14). Three of seven patients in the SB group and two of three patients in the PE group had steroid-resistant rejection that resolved with OKT3 therapy; all of these patients were also converted from cyclosporin/azathioprine to tacrolimus/mycophenolate mofetil maintenance therapy. Two other patients in the SB group were converted to tacrolimus because of intolerance to cyclosporin.
Mean serum creatinine levels were significantly lower in the PE group compared with the SB group at 3 and 6 months after transplantation (Fig. 4) . Glycemic control was excellent in both groups; all but one patient remained insulinindependent, with fasting normoglycemia and normal HbA1c levels. Moreover, all patients had normal OGTT results at 3 months. The blood glucose values during OGTT were similar at all time points in the two groups (Fig. 5 ). Fasting insulin levels were significantly lower in the PE group (84 Ϯ 46 vs. 135 Ϯ 62 pmol/L; P ϭ .01). However, after oral glucose administration, there were no significant differences in the insulin levels at each time point or in the insulin area under the curve (69,976 Ϯ 28,310 and 80,186 Ϯ 38,469 pmol/mL/300 min in the PE and SB groups, respectively). The mean daily prednisone dose was 16.4 Ϯ 2.7 mg and 17.5 Ϯ 2.9 mg in the PE and SB groups, respectively, at the time the OGTTs were performed (not significant).
DISCUSSION
Our results show that PE drainage of pancreas allografts can be performed safely and successfully, with patient and graft survival rates comparable to those with the standard technique of SB drainage. PE drainage provided clear clinical and physiologic advantages over the standard technique. Enteric drainage eliminated the problems of dehydration and metabolic acidosis, which were frequently associated with bladder drainage. In addition, portal venous drainage of insulin provided excellent glycemic control, with significantly lower fasting peripheral insulin levels.
Despite the obvious physiologic attractiveness of PE drainage, most programs continue to use SB drainage. 10, 13 This may be partly due to the perception that the PE technique is more difficult to perform, and that it might compromise graft survival. In our study, however, the mean surgical time and blood transfusion requirements were similar for both procedures, and graft outcomes were equivalent. Importantly, the rate of venous thrombosis of the pancreas graft was not increased with portal venous drainage. Indeed, with either method, we have not lost a graft from thrombosis to date, although we have detected nonocclusive thrombus in several grafts. There are instances, however, where anatomical characteristics (e.g., size, position) of the superior mesenteric vein may preclude portal venous drainage. In 2 of our last 10 patients, we opted for systemic-venous and enteric drainage because the diameter of the superior mesenteric vein was less than 1 cm. Another potential difficulty with the portal venous drainage technique is that the donor arterial iliac bifurcation graft may be too short, particularly if the anastomosis must be made to the native external iliac artery because of proximal atherosclerotic disease. However, the routine use of a donor innominate artery interposition graft has overcome this problem. 12 Portal venous delivery of insulin led to lower fasting peripheral insulin levels, as expected. 9,10,14 A pivotal unanswered question, however, is whether lower insulin levels offer any significant clinical benefits. There is evidence that chronic hyperinsulinemia in combination with increased insulin resistance increases the risk of developing cardiovascular disease directly, [15] [16] [17] [18] and indirectly through promoting an atherogenic lipoprotein milieu and elevating blood pressure. 19 -23 However, long-term clinical data specifically examining this issue are unavailable. Peripheral insulin levels and total insulin area under the curve during OGTT were similar in the two groups of patients in our study. These results contrast with those of Gaber et al, 10 who showed that insulin levels were significantly lower with portal than systemic venous drainage during OGTT 6 months after transplantation. There are important differences in the way these tests were conducted, however, that may account for the discrepancy between their results and ours. First, our patients were tested 3 months after transplantation, when the prednisone dosage was greater, which would be expected to result in greater insulin resistance and greater compensatory insulin secretion, thus diminishing potential differences between the groups. Second, we did not adjust the dose of glucose administered according to the patient's weight. The ability of OGTT to detect differences between portal and systemic insulin delivery is also limited by variability of intestinal transit and absorption rates, which can vary enormously in pancreas transplant recipients because of autonomic enteropathy.
Our study confirms the advantages of primary enteric drainage over bladder drainage of exocrine secretions reported by others. 8, 24 The incidence of dehydration and metabolic acidosis was significantly reduced, and oral bicarbonate supplementation was no longer required. In addition, the need for subsequent conversion from bladder to enteric drainage, which has been reported to be required in 20% to 30% of patients with bladder-drained pancreas, was eliminated. 4 Renal function, as measured by serum creatinine levels, was also better in the PE than in the SB group 3 and 6 months after transplantation; the absence of dehydration in the PE group was a likely contributing factor. We have generally found that the elimination of these metabolic problems has greatly simplified the postoperative management of these patients. Further, although this study did not specifically address the costs involved with transplantation, patients with enteric drainage used outpatient medical services significantly less often than those with bladder drainage.
We did not find a significant difference in the incidence of urinary tract infections and other infectious complications between bladder and enteric drainage, which contrasts with the results of others. 5, 8, 25 The incidence of CMV infection was lower in the PE than in the SB group. A higher prevalence of CMV donor-recipient mismatch may be one factor contributing to this difference, although Pirsch et al 25 also reported a lower incidence of CMV infection with enteric versus bladder drainage. One potential disadvantage of enteric drainage is the inability to monitor urine amylase levels, which can be used to detect rejection of bladderdrained grafts. 26 However, in our experience this type of monitoring has not been particularly helpful in the management of synchronous kidney-pancreas allograft recipients, because rejection usually manifests in the kidney graft first, and this can be monitored easily by following the serum creatinine level.
Refinements in immunosuppressive therapy have dramatically reduced the incidence of acute rejection after synchronous pancreas-kidney transplantation during the past decade. In our study, the overall incidence of acute rejection was 25%, similar to that reported recently by others. [27] [28] [29] Portal venous drainage of pancreas grafts may provide some immunologic advantages as well. Studies in experimental animal models have shown that portal vein delivery of antigen induces antigen-specific hyporesponsiveness and promotes long-term allograft survival, whereas systemic delivery of antigen leads to immunity. 30 -32 These findings have been attributed to the unique processing and presentation of antigen by liver antigen-presenting cells. Recent reports indicate that the incidence of pancreas rejection is lower with portal venous drainage compared with systemic venous drainage. 33 In our study, there appears to be a trend toward less rejection with portal venous drainage (15% vs. 37%), but this did not achieve statistical significance. Longer follow-up is required to clarify this issue.
In summary, our results confirm that PE drainage of pancreas allografts can be performed safely with a high rate of success. Enteric drainage of exocrine secretions eliminated the metabolic and urologic complications commonly associated with bladder drainage. Although the present report focused on the clinical outcome of patients receiving PE versus SB pancreas-kidney transplantation, perhaps a more important and as yet unanswered question relates to the different impact of the two procedures on carbohydrate and lipoprotein metabolism. Systemic insulin delivery is not physiologic and results in loss of the normal portal-systemic insulin gradient, peripheral hyperinsulinemia, and insulin resistance. This is likely to have a major impact on metabolic homeostasis, with potential long-term ramifications. Detailed studies designed to examine these effects of the two transplantation procedures are under way in our institution. Until these issues are resolved, it is at least reassuring to know that the clinical outcome of patients receiving the more physiologic PE procedure is as good, if not better, than those undergoing the traditional SB procedure.
